Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL 35233-1711, United States.
Antiviral Res. 2012 May;94(2):111-25. doi: 10.1016/j.antiviral.2012.02.012. Epub 2012 Mar 8.
Investments in the development of new drugs for orthopoxvirus infections have fostered new avenues of research, provided an improved understanding of orthopoxvirus biology and yielded new therapies that are currently progressing through clinical trials. These broad-based efforts have also resulted in the identification of new inhibitors of orthopoxvirus replication that target many different stages of viral replication cycle. This review will discuss progress in the development of new anti-poxvirus drugs and the identification of new molecular targets that can be exploited for the development of new inhibitors. The prototype of the orthopoxvirus group is vaccinia virus and its replication cycle will be discussed in detail noting specific viral functions and their associated gene products that have the potential to serve as new targets for drug development. Progress that has been achieved in recent years should yield new drugs for the treatment of these infections and might also reveal new approaches for antiviral drug development with other viruses.
在正痘病毒感染新药研发方面的投入，促进了新的研究途径，加深了对正痘病毒生物学的理解，并产生了目前正在临床试验中进展的新疗法。这些基础广泛的努力还导致了识别新的正痘病毒复制抑制剂，这些抑制剂针对病毒复制周期的许多不同阶段。这篇综述将讨论新的抗痘病毒药物的开发进展以及鉴定可用于开发新抑制剂的新分子靶标。正痘病毒组的原型是天花病毒，其复制周期将被详细讨论，注意特定的病毒功能及其相关的基因产物，这些功能和产物有可能成为药物开发的新靶点。近年来取得的进展应该会为这些感染的治疗提供新的药物，也可能为其他病毒的抗病毒药物开发揭示新的方法。
